The Microbiome Therapeutics Innovation Group (MTIG) is a coalition of companies leading the research and development of FDA-approved microbiome therapeutics and microbiome-based products to address unmet medical needs, improve clinical outcomes, and reduce health care costs. The human microbiome is one of the new frontiers of medical innovation that has the potential to benefit patients suffering from numerous diseases afflicting millions of patients and consuming billions of dollars of healthcare resources. MTIG is committed to working with stakeholders who share in our mission and seek tangible policy and regulatory solutions in the emerging microbiome arena. Through a collective voice, the MTIG membership works together to enhance the regulatory, investment, and commercial environment to accelerate microbiome therapeutic product development and enable the field to reach its potential to benefit patients. Today, MTIG is comprised of eleven microbiome therapeutics companies: Alveolus Bio, Bio-Me, BiomeSense, Genetic Analysis, Microba Life Sciences, Rebiotix Inc., Seres Therapeutics, Inc., Servatus Biopharmaceuticals, Siolta Therapeutics, Takeda Pharmaceutical Company Limited and Vedanta Biosciences.